Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Based on the search results and the query, this is information about the combination therapy of oxacillin, benzylpenicillin, ceftriaxone, doxycycline, and clindamycin. The combination "oxacillin + benzylpenicillin + ceftriaxone + doxycycline + clindamycin" appears to be a specific antibiotic combination therapy. From the search results, we can see information about some of the individual components, particularly doxycycline and clindamycin, which are sometimes used together in combination therapies for certain infections. ## Individual Components **Doxycycline** is a tetracycline antibiotic used to treat various bacterial infections including respiratory tract infections, Lyme disease, and acne. It works by stopping bacterial growth[4][7][9]. **Clindamycin** is a lincosamide antibiotic used to treat serious infections caused by susceptible anaerobic bacteria, streptococci, staphylococci, and pneumococci. It's available in oral, topical, and injectable forms[4][5][6][8][10]. The search results don't provide specific information about oxacillin, benzylpenicillin, or ceftriaxone, but these are all antibiotics: - Oxacillin is a penicillinase-resistant penicillin - Benzylpenicillin (also known as penicillin G) is a natural penicillin - Ceftriaxone is a third-generation cephalosporin ## Combination Use While the exact combination of all five antibiotics isn't specifically mentioned in the search results, there is information about antibiotic combinations: 1. Clindamycin-doxycycline-metronidazole combination therapy has been used for treating Babesia gibsoni infections in dogs[1][2]. 2. Doxycycline is often used as a first-line drug for tick-borne illnesses, but combination therapy may be required for certain infections like Babesia[9]. This specific five-antibiotic combination would likely only be used in very specific clinical situations requiring broad-spectrum coverage against multiple types of bacteria, possibly for severe, polymicrobial, or resistant infections. The combination would provide coverage against: - Gram-positive bacteria (all components) - Gram-negative bacteria (particularly ceftriaxone and doxycycline) - Anaerobic bacteria (particularly clindamycin) - Atypical organisms (doxycycline) Such a broad combination would be unusual in standard practice and would typically only be used in specific clinical scenarios under specialist guidance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, and Clindamycin Combination.